NCT01563926 is a Phase 3 clinical trial of somatropin in Growth Hormone Disorder, sponsored by Novo Nordisk A/S.

Who is sponsoring NCT01563926?

NCT01563926 is sponsored by Novo Nordisk A/S.

What drugs are being tested in NCT01563926?

Interventions in NCT01563926: somatropin.

What condition does NCT01563926 study?

NCT01563926 studies Growth Hormone Disorder, Growth Hormone Deficiency in Children, Genetic Disorder, Turner Syndrome.

Is NCT01563926 still recruiting?

NCT01563926 is currently completed. Last updated 27 February 2017.

Last reviewed 2017-02-27 · How we verify

NCT01563926

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluating Acceptance of New Liquid Somatropin Formulation in Children With Growth Hormone Deficiency

Completed Phase 3 Last updated 27 February 2017

What this trial tests

Phase 3 trial testing somatropin in Growth Hormone Disorder in 168 participants. Completed in 10 October 2002.

Timeline

23 October 2000

Primary endpoint
10 October 2002

10 October 2002

Quick facts

Lead sponsor	Novo Nordisk A/S
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	168
Start date	23 October 2000
Primary completion	10 October 2002
Estimated completion	10 October 2002
Sites	6 locations across Israel

Drugs / interventions tested

somatropin (Somatropin) — full drug profile →

Conditions studied

Growth Hormone Disorder — all drugs for Growth Hormone Disorder →
Growth Hormone Deficiency in Children — all drugs for Growth Hormone Deficiency in Children →
Genetic Disorder — all drugs for Genetic Disorder →
Turner Syndrome — all drugs for Turner Syndrome →

Sponsor

Novo Nordisk A/S — full company profile →

Who can join

Eligibility, any sex, with Growth Hormone Disorder or Growth Hormone Deficiency in Children. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial is conducted in Asia. The aim of this trial is to evaluate the new liquid somatropin formulation in children with growth hormone deficiency.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of somatropin

Trials testing the same drug.

NCT02726542 — Augmenting Growth Hormone to Ameliorate Nonalcoholic Fatty Liver Disease in Adolescents · EARLY_PHASE1 · completed
NCT02382939 — A Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Prev · Phase 3 · completed
NCT02229851 — Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropi · Phase 3 · completed
NCT02092077 — A Phase 2, Safety and Dose-Finding Study in Treatment-Naive, Pre-Pubertal, Growth Hormone-Deficient Children · Phase 2 · terminated
NCT01973244 — A Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Long-acting Growth · Phase 1 · completed

Other Novo Nordisk A/S trials

Trials by the same sponsor.

NCT07357740 — A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes · Phase 2 · not yet recruiting
NCT07282613 — A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adoles · Phase 3 · not yet recruiting
NCT07357766 — A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight · Phase 3 · not yet recruiting
NCT07564414 — A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obe · Phase 3 · not yet recruiting
NCT07400107 — AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Exc · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01563926 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novo Nordisk A/S
Last refreshed: 27 February 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01563926.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing